Graham Fulford, founder of GFCT and GFCT Focal Therapy, was diagnosed with prostate cancer early this year. An update from Graham: 

My Personal Journey Continues 

Dear all, 

I mentioned in my last update that I was having a Prostatype test as part of my ongoing active surveillance and I can report that the results are now in. 

They indicate that I'm at low risk of mortality from prostate cancer in the next 10 years - so it's off to the pub to celebrate later! 

As a double check, my consultant urologist will be organising a follow up colour contrast MRI scan in October and he's also organising a flow test and bladder scan in July to try to see if there's anything else contributing to the number of night time visits to the boys room. In the meantime, at least I'm catching up on the book reading. Kindles are a wonderful thing to help avoid disturbing one's long suffering partner in the night! 

The Prostatype score (P-Score) is a prognostic biomarker that integrates a three gene (IGFBP3, F3 and VGLL3) signature derived from prostate biopsy samples, with key clinical parameters, including prostate-specific antigen (PSA) levels, Gleason grade, and tumour stage at diagnosis. It may only be applied on biopsy from male individuals where a core needle biopsy procedure has confirmed the diagnosis of prostate cancer of Gleason score 6 or higher. The Prostatype result should always be used in combination with other clinical and patient specific information. 

The test is available through Pamela Trickett at Cambridge Clinical Laboratories and in my opinion is a very useful addition to the decision making process for men like me on active surveillance. 

Next instalment late July/August. 

Regards, 

Graham